Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Issue 1

Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation

Authors Pickett A

Received 23 April 2013

Accepted for publication 24 April 2013

Published 5 September 2013 Volume 2013:5(1) Pages 149—152


Checked for plagiarism Yes

Download Article [PDF] 

Andy Pickett1,2

1Toxin Science Limited, Wrexham, UK; 2Botulinum Research Center, University of Massachusetts (UMASS), North Dartmouth, MA, USA

One of the most surprising and, at the same time, most frustrating aspects of the continual rise in the use of botulinum toxin type A (BoNT-A), particularly in aesthetic applications, is the sheer number of reviews currently being published. So far in 2013, there have been seven single or joint reviews of BoNT products focusing on facial aesthetics. The frustrating aspects of these reviews cover two areas: Firstly, they inevitably speculate about why there are "apparent differences" between the products. They attempt to use the science of BoNT-A to explain these differences. This speculation is both inappropriate and weak. In fact, the majority of differences between the products seen clinically are, by far, due to simple dose differences used in studies, especially when two or more products are being compared.

View original paper by Prager.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]